BEAT Earnings Prediction
The chart below shows how BEAT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BEAT sees a -5.31% change in stock price 10 days leading up to the earnings, and a +5.54% change 10 days following the report. On the earnings day itself, the stock moves by -0.28%. This data can give you a slight idea of what to expect for the next quarter's release.
BEAT Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.19
-46.15%
-0.00%
No Data Available
BEAT Earnings Analysis
Heartbeam, Inc. Common Stock Corporation (BEAT.O) Earnings Conference Call
Positive
Innovative Cardiac Care Technology: Heart Beam has developed core technology that enables a new paradigm in cardiac care.
Innovative Cable-Free ECG: Heart Beam's developed the first ever cable-free 12-lead ECG that patients can use wherever they are.
Enhanced Data Capture: This allows users to capture the highest resolution data possible in a patient carried device, far greater than with existing wearables.
Market Potential Assessment: We believe that there are multiple large markets where our technology is applicable, and together, these addressable markets are worth more than $100 billion per year in the U.S. alone.
Market Disruption Strategy: Heart Beam is well positioned to disrupt these markets with a strategy that starts with symptom-driven diagnosis moves to monitoring and screening and ultimately to replacing traditional 12-lead ECGs in hospitals and beyond as a new standard of care.
Negative
Third Quarter Net Loss: Net loss for the third quarter ending 30 September 2024 was just under $5 million, $4.979 million.
Net Cash in Operations: When adjusted for non-cash items such as share-based compensation and timing differences, the net cash used in operating activities was just $3.3 million, which is more heavily weighted to our R&D and clinical initiatives than the G&A.
Cash Balance Update: The cash balance at 30 September 2024 was $5.8 million.
Revenue Expectations for 2025: We don't anticipate significant revenue in 2025.
Quarterly Net Loss: We have a net loss for the third quarter of $4.979 million.
BEAT FAQs
How does BEAT typically perform around its earnings report dates?
Is HeartBeam, Inc. (BEAT) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BEAT Earning Call Sentiment
HeartBeam, Inc. (BEAT) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
BEAT.O
-1.44%Positive
The earnings call reveals significant challenges, including a net loss increase, low cash reserves, and uncertainties around FDA clearance. The Q&A section highlights management's evasiveness on key issues like FDA timelines and study results, raising concerns. Despite optimism about future growth and AI integration, the immediate financial and regulatory hurdles, along with competitive pressures, overshadow potential positives. Thus, the overall sentiment is negative, indicating potential stock price decline in the short term.
